Individual and Community Factors Associated with Naloxone Co-prescribing Among Long-term Opioid Patients

A Retrospective Analysis

Published in: Journal of General Internal Medicine (2021). doi: 10.1007/s11606-020-06577-5

Posted on RAND.org on February 19, 2021

by Bradley D. Stein, Rosanna Smart, Christopher M. Jones, Yaou Flora Sheng, David Powell, Mark J. Sorbero

Read More

Access further information on this document at Springer Nature

This article was published outside of RAND. The full text of the article can be found at the link above.

Background

Naloxone co-prescribing to individuals at increased opioid overdose risk is a key component of opioid overdose prevention efforts.

Objective

Examine naloxone co-prescribing in the general population and assess how co-prescribing varies by individual and community characteristics.

Design

Retrospective cross-sectional study. We conducted a multivariable logistic regression of 2017–2018 de-identified pharmacy claims representing 90% of all prescriptions filled at retail pharmacies in 50 states and the District of Columbia.

Patients

Individuals with opioid analgesic treatment episodes > 90 days.

Main Measures

Outcome was co-prescribed naloxone. Predictor variables included insurance type, primary prescriber specialty, receipt of concomitant benzodiazepines, high-dose opioid episode, county urbanicity, fatal overdose rates, poverty rates, and primary care health professional shortage areas.

Key Results

Naloxone co-prescribing occurred in 2.3% of long-term opioid therapy episodes. Medicaid (aOR 1.87, 95%CI 1.84 to 1.90) and Medicare (aOR 1.48, 95%CI 1.46 to 1.51) episodes had higher odds of naloxone co-prescribing than commercial insurance episodes, while cash pay (aOR 0.77, 95%CI 0.74 to 0.80) and other insurance episodes (aOR 0.81, 95%CI 0.79 to 0.83) had lower odds. Odds of naloxone co-prescribing were higher among high-dose opioid episodes (aOR 3.19, 95%CI 3.15 to 3.23), when concomitant benzodiazepines were prescribed (aOR 1.12, 95%CI 1.10 to 1.14), and in counties with higher fatal overdose rates.

Conclusion

Co-prescription of naloxone represents a tangible clinical action that can be taken to help prevent opioid overdose deaths. However, despite recommendations to co-prescribe naloxone to patients at increased risk for opioid overdose, we found that co-prescribing rates remain low overall. States, insurers, and health systems should consider implementing strategies to facilitate increased co-prescribing of naloxone to at-risk individuals.

Research conducted by

This report is part of the RAND Corporation External publication series. Many RAND studies are published in peer-reviewed scholarly journals, as chapters in commercial books, or as documents published by other organizations.

The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.